Identification of the Potential Molecular Mechanisms Linking RUNX1 Activity with Nonalcoholic Fatty Liver Disease, by Means of Systems Biology
Authors:
- Laia BertranLaia Bertran
- Ailende Eigbefoh-AddehAEAilende Eigbefoh-Addeh
- Marta Portillo-CarrasquerMPMarta Portillo-Carrasquer
- Andrea Barrientos-RiosalidoABAndrea Barrientos-Riosalido
- Jessica BinettiJBJessica Binetti
- Carmen AguilarCACarmen Aguilar
- Javier Ugarte ChicoteJCJavier Ugarte Chicote
- Helena BartraHBHelena Bartra
- Laura ArtigasLALaura Artigas
- Mireia ComaMCMireia Coma
- Cristóbal RichartCRCristóbal Richart
- Teresa AuguetTATeresa Auguet
Open Access
- 3 June 2022
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 10 (6) , 1315
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic hepatic disease; nevertheless, no definitive diagnostic method exists yet, apart from invasive liver biopsy, and nor is there a specific approved treatment. Runt-related transcription factor 1 (RUNX1) plays a major role in angiogenesis and inflammation; however, its link with NAFLD is unclear as controversial results have been reported. Thus, the objective of this work was to determine the proteins involved in the molecular mechanisms between RUNX1 and NAFLD, by means of systems biology. First, a mathematical model that simulates NAFLD pathophysiology was generated by analyzing Anaxomics databases and reviewing available scientific literature. Artificial neural networks established NAFLD pathophysiological processes functionally related to RUNX1: hepatic insulin resistance, lipotoxicity, and hepatic injury-liver fibrosis. Our study indicated that RUNX1 might have a high relationship with hepatic injury-liver fibrosis, and a medium relationship with lipotoxicity and insulin resistance motives. Additionally, we found five RUNX1-regulated proteins with a direct involvement in NAFLD motives, which were NFκB1, NFκB2, TNF, ADIPOQ, and IL-6. In conclusion, we suggested a relationship between RUNX1 and NAFLD since RUNX1 seems to regulate NAFLD molecular pathways, posing it as a potential therapeutic target of NAFLD, although more studies in this field are needed.Keywords
Funding Information
- Teresa Auguet (PV20062N)
This publication has 112 references indexed in Scilit:
- Annotating Cancer Variants and Anti-Cancer Therapeutics in ReactomeCancers, 2012
- Nucleolar AATF regulates c-Jun–mediated apoptosisMolecular Biology of the Cell, 2012
- Diacylglycerol Activation of Protein Kinase Cε and Hepatic Insulin ResistanceCell Metabolism, 2012
- Cellular mechanism of insulin resistance in nonalcoholic fatty liver diseaseProceedings of the National Academy of Sciences, 2011
- NF-κB in the liver—linking injury, fibrosis and hepatocellular carcinomaNature Reviews Gastroenterology & Hepatology, 2011
- Phosphorylation of RUNX1 by Cyclin-dependent Kinase Reduces Direct Interaction with HDAC1 and HDAC3Journal of Biological Chemistry, 2011
- Differential roles of PKCα and PKCɛ in controlling the gene expression of Nox4 in human endothelial cellsFree Radical Biology and Medicine, 2008
- Specific protein kinase C isoforms as transducers and modulators of insulin signalingMolecular Genetics and Metabolism, 2006
- BioGRID: a general repository for interaction datasetsNucleic Acids Research, 2006
- Development of Human Protein Reference Database as an Initial Platform for Approaching Systems Biology in HumansGenome Research, 2003